Trials in Colorado.
63 APOE4-relevant Alzheimer’s trials run in Colorado — 30 of them recruiting. Each one translated into plain English, with our read on what it means for an APOE4 carrier.
- Non-carriers only, not for APOE4NCT00574132Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)
This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…
- Drug trial for diagnosed APOE4 carriersNCT00575055Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)
This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…
- Carriers enrolled, but higher ARIA riskNCT01767311A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…
- Built exclusively for APOE 4/4 carriersNCT02565511A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…
- Built specifically for APOE4 carriersNCT03131453A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…
- Open to carriers, but ARIA risk elevatedNCT03887455A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…
- Enrolled carriers, prior data unfavorableNCT00348309Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease
This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…
- APOE4 stratified, suggests less benefitNCT00428090Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…
- Drug trial, genotype not specified in sourceNCT00667810Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…
- Drug trial, not APOE4-specific, carriers at riskNCT00676143Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…
- Drug extension study, prior participants onlyNCT00998764A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients
This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…
- Huntington's study, not about APOE4NCT01574053Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…
- Open to carriers, not 4-specificNCT02245737An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…
- Unrelated to APOE4 or Alzheimer'sNCT02855476HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
HDClarity is collecting cerebrospinal fluid and blood samples from people at various stages of Huntington's disease, plus healthy controls, across multiple…
- Observational only, no treatment involvedNCT02951598A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)
This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…
- Discontinued trial, not APOE4-specificNCT02972658A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…
- Not APOE4-related, movement disorder focusNCT03924414Trial of Parkinson's And Zoledronic Acid
This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…
- Observational only, genotype not specifiedNCT03944603Longitudinal Innate Immunity and Aging Study
This observational study tracks healthy adults ages 60 to 89 over two years to understand how immune system markers in blood and spinal fluid relate to…
- Open to carriers, not 4-specificNCT04033510Acute Cognitive Changes During Atrial Fibrillation Episodes (AFCOG)
This study tests whether people with atrial fibrillation (an irregular heart rhythm) think and remember less clearly during an AF episode than when their heart…
- Huntington's trial, not relevant to APOE4NCT04120493Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease
This trial tests AMT-130, a gene therapy delivered by brain surgery into a deep brain region called the striatum, in adults with early Huntington's disease. It…
- Not relevant to APOE4 carriersNCT04165109Trial-Ready Cohort-Down Syndrome (TRC-DS)
This is not a treatment trial. It is a study building a pool of adults with Down syndrome, ages 25 to 55, who are ready to be recruited into future Alzheimer's…
- FTLD-focused, not APOE4-relevantNCT04363684ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
This is a large North American research registry and natural history study tracking people with frontotemporal lobar degeneration (FTLD) and related conditions…
- High ARIA risk for carriersNCT04437511A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…
- Open to carriers, not 4-specificNCT04902703Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease
This trial is testing sargramostim, an FDA-approved bone marrow drug, to see whether it can slow cognitive decline in people who already have mild-to-moderate…
- Observational only, genotype not specifiedNCT04916210Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
The DISCOVERY study is an observational study — no drug or treatment is being tested. Researchers are following stroke survivors over time, collecting…
- Drug trial, genotype not specified, ARIA riskNCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…
- Open to carriers, not 4-specificNCT05399888A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
This Phase 2 trial is testing BIIB080, a drug injected into the spinal fluid, to see whether it can slow cognitive decline in people with mild cognitive…
- Open to carriers, not genotype-specificNCT05421728Effectiveness of Engaging in Advance Care Planning Talks (ENACT) Group Visits in Primary Care for Older Adults With and Without Alzheimer's Disease
This trial tests whether group conversations about advance care planning, led by a geriatrician and social worker in a primary care setting, help older adults…
- Anti-amyloid drug — carriers face higher ARIA riskNCT05463731A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…
- Open to carriers, not 4-specificNCT05479552A Diagnostic Test for Dementia With Lewy Bodies
This study is testing a diagnostic tool called the Syn-One Test, which looks for a protein called alpha-synuclein in a skin biopsy. The goal is to better…
- Open to carriers, not 4-specificNCT05511363A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…
- Early Alzheimer's drug trial, not 4-specificNCT05531526Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
This trial tests whether a pill called AR1001 can slow memory and thinking decline in people with early Alzheimer's, compared with a placebo. It also checks…
- Different gene and disease, not APOE4-focusedNCT05677880Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL) Study
This is an observational study, meaning no drug or treatment is being given. Researchers will follow people with CADASIL, a rare inherited small-vessel brain…
- Not relevant to APOE4 or Alzheimer'sNCT05686551GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
This trial is testing tominersen, a drug injected into the spinal fluid, against a placebo in people with prodromal or early Huntington's Disease. The goal is…
- Late-stage dementia care, not preventionNCT05820919Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
This trial is testing a structured staff-led program called LOCK — focused on light exposure, activity, and consistent routines — to improve sleep in nursing…
- Symptomatic MCI only, not 4-specificNCT05822362CBD for Individuals at Risk for Alzheimer's Disease
This trial tests whether cannabidiol (CBD), a compound from the cannabis plant, changes blood and brain markers linked to Alzheimer's progression, along with…
- Care-quality study, not APOE4-specificNCT05877391Intervention to Collect and Utilize Sexual Orientation and Gender Identity (SOGI) Information in Hospice
This study tests a training program for hospice staff on talking with patients and families, including how to ask about sexual orientation and gender identity.…
- Late-stage AD only, genotype not relevantNCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…
- Symptomatic dementia drug trial, not APOE4-specificNCT06125951Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
This trial tests whether a once-daily 10 mg pill called Xanamem can safely affect thinking and daily function in people who already have mild or moderate…
- Not about APOE4; requires TTR variantNCT06563895Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
This trial tests whether a daily pill called acoramidis can delay or prevent heart or nerve damage in people who carry an inherited TTR gene variant but have…
- Not APOE4-specific; for diagnosed patientsNCT06638632Decision Aid for Dementia Therapies
This study is building a decision aid, a tool that helps people with early memory problems and their families think through medication choices for dementia. It…
- Drug trial, APOE4 handling not statedNCT06653153A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…
- Unrelated to APOE4 or Alzheimer'sNCT06667414Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
This study is mapping specific genetic markers called SNPs in people who carry the Huntington's disease gene mutation. Participants give a blood sample and…
- HIV-specific trial, genotype not relevantNCT06705478Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV
This Phase 2 trial is comparing two medications — pramipexole (a dopamine-targeting drug used in Parkinson's and restless legs) and escitalopram (a common…
- Drug trial, genotype not specifiedNCT06709014A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
This trial tests whether buntanetap, a daily pill, slows memory and thinking decline and helps everyday function in adults 55 to 85 with early Alzheimer's. It…
- Open to carriers, not 4-specificNCT06808984Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
This trial tests BMS-986368, an experimental drug that works on the body's endocannabinoid system, to see whether it reduces agitation in people who already…
- Open to carriers, not 4-specificNCT06847321Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
This Phase 2 trial is testing LHP588, an oral capsule taken once daily, in people with mild to moderate Alzheimer's disease who also test positive for P.…
- Open to patients, genotype not requiredNCT06881836A Study of ONO-2020 in Participants With Mild to Moderate Alzheimer's Disease
This trial tests ONO-2020, an experimental pill that works on gene regulation, in people already diagnosed with mild to moderate Alzheimer's. Researchers want…
- Drug trial, not for healthy carriersNCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
This trial tests a drug called ML-007C-MA against a placebo in people aged 55 to 90 who already have Alzheimer's and are troubled by hallucinations and…
- Open to carriers, not 4-specificNCT06976203A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
MINDSET 2 is testing KarXT plus KarX-EC — a combination drug regimen that works on muscarinic receptors in the brain — to see whether it improves cognition in…
Copy a forum-ready post
Keep exploring
Educational, not medical advice. Trial decisions belong between you and your physician.